Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.
During the discussion, Radin addresses the findings around the efficacy and safety of the 2 mg dose of semaglutide among this patient population.
3 comments
577673 928284I recognize there is surely an excellent deal of spam on this weblog. Do you want aid cleansing them up? I may assist in between classes! 216453
128260 838526In case you are viewing come up with alter in most of the living, starting point usually L . a . Weight reduction cutting down on calories platform are a wide stair as part of your attaining that most agenda. weight loss 414279
6224 160984if the buffalo in my head could speak german i would not know a god damm thing. What i do know is that the language of art is out of this world. 850911